SZSE:002294 (China)
Â
Class A
Â¥
39.65
+0.20 (+0.51%)
Apr 25
What is a stock summary page? Click here for an overview.
Business Description
Shenzhen Salubris Pharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000FW8
Share Class Description:
SZSE:002294: Class ACompare
Compare
Traded in other countries / regions
002294.China Index Membership
SZSE Component IndexSZSE SME Price IndexCSI 500 IndexCSI 300 Index IPO Date
2009-09-10Description
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.16 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.24 | |||||
| Interest Coverage | 46.18 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 17.16 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.9 | |||||
| 3-Year EBITDA Growth Rate | 2.4 | |||||
| 3-Year EPS without NRI Growth Rate | 23.6 | |||||
| 3-Year FCF Growth Rate | -8.5 | |||||
| 3-Year Book Growth Rate | 2.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 20.35 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.07 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.36 | |||||
| 9-Day RSI | 74.39 | |||||
| 14-Day RSI | 72.6 | |||||
| 3-1 Month Momentum % | 0.8 | |||||
| 6-1 Month Momentum % | -8.26 | |||||
| 12-1 Month Momentum % | -2.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.23 | |||||
| Quick Ratio | 3.75 | |||||
| Cash Ratio | 1.68 | |||||
| Days Inventory | 170.67 | |||||
| Days Sales Outstanding | 47.68 | |||||
| Days Payable | 48.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.26 | |||||
| Dividend Payout Ratio | 0.75 | |||||
| Forward Dividend Yield % | 1.26 | |||||
| 5-Year Yield-on-Cost % | 1.26 | |||||
| Shareholder Yield % | 1.41 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.69 | |||||
| Operating Margin % | 19.21 | |||||
| Net Margin % | 15.1 | |||||
| FCF Margin % | 11.86 | |||||
| ROE % | 7.11 | |||||
| ROA % | 5.94 | |||||
| ROIC % | 9.87 | |||||
| 3-Year ROIIC % | 8.94 | |||||
| ROC (Joel Greenblatt) % | 25.98 | |||||
| ROCE % | 7.13 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 73.43 | |||||
| Forward PE Ratio | 64.47 | |||||
| PE Ratio without NRI | 59.71 | |||||
| Shiller PE Ratio | 45.57 | |||||
| Price-to-Owner-Earnings | 421.81 | |||||
| PEG Ratio | 7.66 | |||||
| PS Ratio | 11.11 | |||||
| PB Ratio | 4.96 | |||||
| Price-to-Tangible-Book | 7.32 | |||||
| Price-to-Free-Cash-Flow | 93.5 | |||||
| Price-to-Operating-Cash-Flow | 39.23 | |||||
| EV-to-EBIT | 65.47 | |||||
| EV-to-Forward-EBIT | 35.22 | |||||
| EV-to-EBITDA | 65.47 | |||||
| EV-to-Forward-EBITDA | 29.4 | |||||
| EV-to-Revenue | 10.62 | |||||
| EV-to-Forward-Revenue | 6.56 | |||||
| EV-to-FCF | 86.04 | |||||
| Price-to-GF-Value | 1.16 | |||||
| Price-to-Projected-FCF | 3.49 | |||||
| Price-to-Median-PS-Value | 1.26 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.39 | |||||
| Price-to-Graham-Number | 4.41 | |||||
| Price-to-Net-Current-Asset-Value | 14.96 | |||||
| Price-to-Net-Cash | 360.45 | |||||
| Earnings Yield (Greenblatt) % | 1.53 | |||||
| FCF Yield % | 1.07 | |||||
| Forward Rate of Return (Yacktman) % | 21.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Salubris Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,983.469 | ||
| EPS (TTM) (Â¥) | 0.54 | ||
| Beta | 0.98 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | 32.2 | ||
| 14-Day RSI | 72.6 | ||
| 14-Day ATR (Â¥) | 1.573951 | ||
| 20-Day SMA (Â¥) | 34.8625 | ||
| 12-1 Month Momentum % | -2.62 | ||
| 52-Week Range (Â¥) | 25.51 - 41.27 | ||
| Shares Outstanding (Mil) | 1,114.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Salubris Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Salubris Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenzhen Salubris Pharmaceuticals Co Ltd Frequently Asked Questions
What is Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294)'s stock price today?
The current price of SZSE:002294 is ¥39.65. The 52 week high of SZSE:002294 is ¥41.27 and 52 week low is ¥25.51.
When is next earnings date of Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294)?
The next earnings date of Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294) is .
Does Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294) pay dividends? If so, how much?
The Dividend Yield %  of Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294) is 1.26% (As of Today), Highest Dividend Payout Ratio of Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294) was 125. The lowest was 0.37. And the median was 0.8. The  Forward Dividend Yield % of Shenzhen Salubris Pharmaceuticals Co Ltd(SZSE:002294) is 1.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers